Ladybon

Tibolone, the active ingredient in Ladybon, is a synthetic steroid hormone presented as an oral tablet for oral use. It relieves menopausal symptoms and addresses estrogen deficiency in post‑menopausal women. GNH USA supplies Ladybon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ladybon (tibolone) is used within hormone replacement therapy to manage conditions related to estrogen deficiency and menopause.

Menopausal symptoms: reduces hot flashes, night sweats and mood swings. Estrogen deficiency: restores hormonal balance after menopause. Prevention of osteoporosis: helps maintain bone mineral density in post‑menopausal women.

Tibolone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or gastrointestinal discomfort. - Breast tenderness or swelling. - Mood changes or irritability. - Weight gain or fluid retention.

Serious or Rare Side Effects: - Venous thromboembolism: risk of deep vein thrombosis or pulmonary embolism. - Stroke or cerebrovascular events. - Liver dysfunction: elevated enzymes or hepatitis. - Breast cancer: potential increased risk with long‑term use. - Severe allergic reactions: rash, swelling, or anaphylaxis.

Before initiating tibolone therapy, consider the following safety measures.

Monitor liver function: assess hepatic enzymes periodically. Assess cardiovascular risk: evaluate history of thrombosis or stroke. Screen for breast disease: perform regular clinical examinations. Avoid use in pregnancy: contraindicated in women who are pregnant or may become pregnant. Do not use in active malignancy: especially estrogen‑dependent cancers. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Tibolone can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - Hormonal contraceptives: tibolone can diminish contraceptive effectiveness. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase tibolone plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower tibolone exposure. - Selective serotonin reuptake inhibitors (SSRIs): potential additive effect on mood. - Antihypertensive agents: monitor blood pressure for additive hypotensive effect.